Communications Biology (Apr 2021)

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

  • Giorgia Maroni,
  • Mahmoud A. Bassal,
  • Indira Krishnan,
  • Chee Wai Fhu,
  • Virginia Savova,
  • Rapolas Zilionis,
  • Valerie A. Maymi,
  • Nicole Pandell,
  • Eva Csizmadia,
  • Junyan Zhang,
  • Barbara Storti,
  • Julio Castaño,
  • Riccardo Panella,
  • Jia Li,
  • Corinne E. Gustafson,
  • Sam Fox,
  • Rachel D. Levy,
  • Claire V. Meyerovitz,
  • Peter J. Tramontozzi,
  • Kimberly Vermilya,
  • Assunta De Rienzo,
  • Stefania Crucitta,
  • Daniela S. Bassères,
  • Marla Weetall,
  • Art Branstrom,
  • Alessandra Giorgetti,
  • Raffaele Ciampi,
  • Marzia Del Re,
  • Romano Danesi,
  • Ranieri Bizzarri,
  • Henry Yang,
  • Olivier Kocher,
  • Allon M. Klein,
  • Robert S. Welner,
  • Raphael Bueno,
  • Maria Cristina Magli,
  • John G. Clohessy,
  • Azhar Ali,
  • Daniel G. Tenen,
  • Elena Levantini

DOI
https://doi.org/10.1038/s42003-021-01897-6
Journal volume & issue
Vol. 4, no. 1
pp. 1 – 15

Abstract

Read online

Maroni, Bassal, Krishnan et al. characterise human non-small cell lung cancer (NSCLC) carrying Kras-mutations by single-cell RNA sequencing. They identify a tumour-specific population that is conserved in mice and responds to the drug, PTC596, which is currently in clinical trials and may offer a potential avenue for treating aggressive NSCLC expressing mutated Kras.